Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Müllerian tumors

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 154-159

  Penson, Richard T ^a   Dizon, Don S ^a   Cannistra, Stephen A ^a   Roche, Maria R ^a   Krasner, Carolyn N ^a   Berlin, Suzanne T ^a   Horowitz, Neil S ^a   DiSilvestro, Paul A ^a   Matulonis, Ursula A ^a   Lee, Hang ^a   King, Modjulie A ^a   Campos, Susana M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART PALPITATION; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MUCOSA INFLAMMATION; MUELLERIAN DUCT TUMOR; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA; UTERUS TUMOR; VOMITING; ADOLESCENT; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OVARY TUMOR;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 73949092398     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.7900     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004
3. Cannistra S, McGuire W: Progress in the management of gynecologic cancer. J Clin Oncol 25:2865-2866, 2007
4. US Department of Health and Human Services, Centers for Disease Control and Prevention: United States cancer statistics. http://apps.nccd.cdc.gov/uscs/
5. Santin AD, Hermonat PL, Ravaggi A, et al: Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 20:177-181, 1999
6. Cooper BC, Ritchie JM, Broghammer CL, et al: Preoperative serum vascular endothelial growth factor levels: Significance in ovarian cancer. Clin Cancer Res 8:3193-3197, 2002
7. Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997
8. Kim KJ, Li B, Houck K, et al: The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7:53-64, 1992
9. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007
10. Garcia AA, Oza AM, Hirte H, et al: Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J Clin Oncol 23:455s, 2005 (suppl 16S; abstr 5000)
11. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007
12. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
13. Rustin GJ, Bast RC Jr, Kelloff GJ, et al: Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10:3919-3926, 2004
14. Mesiano S, Ferrara N, Jaffe RB: Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immuneneutralization. Am J Pathol 153:1249-1256, 1998
15. Penson RT, Shannon KE, Sharpless NE, et al: Ovarian cancer: An update on genetics and therapy. Compr Ther 24:477-487, 1998
16. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
17. Garcia AA, Hirte H, Fleming G, et al: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26:76-82, 2008
18. Genentech: Avastin (bevacizumab), product insert. Code Revision, 2006. http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf
19. Wright JD, Hagemann A, Rader JS, et al: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 107:83-89, 2006
20. Simpkins F, Belinson JL, Rose PG: Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107:118-123, 2007
21. Micha JP, Goldstein BH, Rettenmaier MA, et al: A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771-776, 2007
22. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003